Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
‘Graft versus Host Disease (GvHD) - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Graft versus Host Disease (GvHD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2016-2027
Graft versus Host Disease (GvHD) Epidemiology
The Graft versus Host Disease (GvHD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Graft versus Host Disease (GvHD) are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
According to Expert, the diagnosed incident cases of Hematopoietic Stem Cell Transplantations (HSCTs) in 7 major markets was 53,601 (which includes 21,408 Incident cases of first allogeneic HSCT) in 2016 and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. Among 7MM United States account for highest diagnosed incident cases of aGvHD and cGvHD in diagnosed incident cases of First Allogeneic HSCTs followed by Germany.
Graft versus Host Disease (GvHD) Epidemiology Segmentation
The disease epidemiology covered in the report is segmented by sub-type [Acute GvHD (aGvHD) and Chronic GvHD (cGvHD)] and grades of aGvHD [I, II, III and IV]. The epidemiology section of report further includes diagnosed incident cases of Hematopoietic Stem Cell Transplantations (HSCTs). It also includes diagnosed incident cases of aGvHD and cGvHD, 4-Year diagnosed prevalent cases of aGvHD and 5-Year diagnosed prevalent cases of cGvHD in diagnosed incident cases of First Allogeneic HSCTs.
The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
Report Scope
• The report covers detailed overview of Graft versus Host Disease (GvHD) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of Graft versus Host Disease (GvHD)
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by sub-type [Acute GvHD (aGvHD) and Chronic GvHD (cGvHD)] and grades of aGvHD [I, II, III and IV]
Key strengths
• 10 Year Forecast of Graft versus Host Disease (GvHD) epidemiology
• 7MM Coverage
• Total Prevalent Cases of Graft versus Host Disease (GvHD)
• Incident Cases according to segmentation: diagnosed incident cases of Hematopoietic Stem Cell Transplantations (HSCTs), diagnosed incident cases of aGvHD and cGvHD, 4-Year diagnosed prevalent cases of aGvHD and 5-Year diagnosed prevalent cases of cGvHD in diagnosed incident cases of First Allogeneic HSCTs
Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2016-2027
Graft versus Host Disease (GvHD) Epidemiology
The Graft versus Host Disease (GvHD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Graft versus Host Disease (GvHD) are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
According to Expert, the diagnosed incident cases of Hematopoietic Stem Cell Transplantations (HSCTs) in 7 major markets was 53,601 (which includes 21,408 Incident cases of first allogeneic HSCT) in 2016 and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. Among 7MM United States account for highest diagnosed incident cases of aGvHD and cGvHD in diagnosed incident cases of First Allogeneic HSCTs followed by Germany.
Graft versus Host Disease (GvHD) Epidemiology Segmentation
The disease epidemiology covered in the report is segmented by sub-type [Acute GvHD (aGvHD) and Chronic GvHD (cGvHD)] and grades of aGvHD [I, II, III and IV]. The epidemiology section of report further includes diagnosed incident cases of Hematopoietic Stem Cell Transplantations (HSCTs). It also includes diagnosed incident cases of aGvHD and cGvHD, 4-Year diagnosed prevalent cases of aGvHD and 5-Year diagnosed prevalent cases of cGvHD in diagnosed incident cases of First Allogeneic HSCTs.
The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
Report Scope
• The report covers detailed overview of Graft versus Host Disease (GvHD) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of Graft versus Host Disease (GvHD)
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by sub-type [Acute GvHD (aGvHD) and Chronic GvHD (cGvHD)] and grades of aGvHD [I, II, III and IV]
Key strengths
• 10 Year Forecast of Graft versus Host Disease (GvHD) epidemiology
• 7MM Coverage
• Total Prevalent Cases of Graft versus Host Disease (GvHD)
• Incident Cases according to segmentation: diagnosed incident cases of Hematopoietic Stem Cell Transplantations (HSCTs), diagnosed incident cases of aGvHD and cGvHD, 4-Year diagnosed prevalent cases of aGvHD and 5-Year diagnosed prevalent cases of cGvHD in diagnosed incident cases of First Allogeneic HSCTs
Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
